Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks;Türk halkinda yeni gelişen koroner hastalik öngördür-dsucüsü olarak serum apolipoprotein B düzeyi LDL-kolesterolden üstün

Anadolu Kardiyoloji Dergisi

Volumn 7, Issue 2, 2007, Pages 128-133

  Onat, Altan ^a,b,f   Özhan, Hakan ^c   Can, Günay ^b   Hergenç, Gülay ^d   Karabulut, Ahmet ^e   Albayrak, Sinan ^c  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^d YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^e DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f NONE   (Turkey)

Author keywords

Abdominal obesity; Apolipoprotein A l and B; Coronary heart disease risk; LDL cholesterol; Turkish Adult Risk Factor study; Turkish adults

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANAMNESIS; ANGINA PECTORIS; ARTICLE; BLOOD ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL EXAMINATION; PREDICTION; REST; RISK ASSESSMENT; SEX DIFFERENCE; TURKEY (REPUBLIC); WAIST CIRCUMFERENCE;

ADULT; AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TURKEY;

EID: 34250019971     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein Al and apolipoprotein B plasma levels. J Intern Med 2006; 259: 437-46.
2. Contois J, McNamara JR, Lammi-Keefe C, Wilson PW, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 507-14.
3. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PW, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 515-23.
4. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/Al ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26: 406-10.
5. Meisinger C, Löwel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26: 271-8.
6. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation 2004; 110: 2824-30.
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004; 364: 937-52.
8. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-l, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
9. Kottke BA, Zinsmeister AR, Holmes DR Jr, Kneller RW, Hallaway BJ, Mao SJT. Apolipoproteins and coronary heart disease. Mayo Clin Proc 1986; 61: 13-20.
10. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94: 273-8.
11. Talmud P J, Hawe E, Miller GJ, Humphries SE: Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged U.K. men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-23.
12. Wagner AM, Sanchez-Quesada JL, Perez A, Rigla M, Cortes M, Blanco-Vaca F, et al. Inaccuracy of calculated LDL cholesterol in type 2 diabetes: consequences for patient risk classification and therapeutic decision. Clin Chem 2000; 46: 1830-2.
13. Onat A, Yildirim B, Uslu N, Gürbüz N, Keleş I, Çetinkaya A, ve ark.: Türk erişkinlerinde plazma lipoprotein ve apolipoproteinleri: Genel düzeyler, risk faktörleriyle ilişkileri ve kadinlarda HDL'nin koroner riski belirleyiciliǧi. Türk Kardiyol Dern Arş 1999; 27; 72-9.
14. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10.
15. Onat A (editör), Sansoy V, Hergenç G, Soydan I, Adalet K. Türk Erişkinlerinde Kalp Saǧliǧi: Halkimiza ilişkin temel veri üretiminden evrensel tibba katkiya. Istanbul: Argos Iletişim; 2005.
16. Hense HW, Stieber J: Blutdruck-Messkurs. Heidelberg: GSF-MEDIS Institut, 1988.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
19. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2006; Atherosclerosis. 2007; 191: 182-90. Epub 2006 May 6.
20. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26: 3160-7.
21. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods, 2nd ed. Geneva: World Health Organization; 1982.
22. Sniderman A, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapo B: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-59.
23. Zunic G, Jelic-Ivanovic Z, Spasic S, Stojiljkovic A, Majkic-Singh N: Reference values for apolipoproteins A-I and B in healthy subjects, by age: Clin Chem 1992; 38: 566-9.
24. Leino A, Impivaara O, Kaitsaari M, Jarvisalo J: Serum concentrations of apolipoprotein A-l, apolipoprotein B, and lipoprotein (a) in a population sample. Clin Chem 1995; 41: 1633-6.
25. Noma A, Hata Y, Goto Y: Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences. Clin Chim Acta 1991; 199: 147-57.
26. Corsetti JP, Zareba W, Moss A J, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 2004; 177: 367-73.
27. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 1991-7.
28. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 2004; 110: 2687-93.